<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868491</url>
  </required_header>
  <id_info>
    <org_study_id>EMR-62202-717</org_study_id>
    <nct_id>NCT00868491</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer</brief_title>
  <official_title>Induction Chemotherapy Followed by Chemoradiation With Cetuximab and Cisplatin for Inoperable Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and toxicity of&#xD;
      docetaxel/cisplatin/5-fluorouracil induction chemotherapy (4 cycles) followed by concomitant&#xD;
      chemoradiation with cetuximab and weekly cisplatin in patients with inoperable squamous cell&#xD;
      carcinoma of the head and neck.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment results with radiotherapy in inoperable squamous cell carcinoma of the head and&#xD;
      neck are poor.&#xD;
&#xD;
      In this proposed single-institution non-randomized, one-arm, open label phase II study, the&#xD;
      authors will test the efficacy and toxicity of docetaxel/cisplatin/5-fluorouracil induction&#xD;
      chemotherapy (4 cycles) followed by concomitant chemoradiation with cetuximab and weekly&#xD;
      cisplatin in patients with inoperable squamous cell carcinoma of the head and neck.&#xD;
&#xD;
      Chemotherapy doses will be as follows: docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V.&#xD;
      day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for&#xD;
      4 cycles followed by cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20,&#xD;
      cisplatin 30 mg/m2 I.V. weeks 14-20. Three-dimensional conformal radiotherapy planning and&#xD;
      delivery (35x2 Gy/day over 7 weeks {weeks 14 - 20}) will be used.&#xD;
&#xD;
      The planned number of patients to be included is 30 and anticipated enrolment period is 12&#xD;
      months.&#xD;
&#xD;
      The primary objective of the study is to determine locoregional control at 2 years&#xD;
      post-therapy, whereas secondary objectives are to determine feasibility (toxicity profile) of&#xD;
      the proposed regimen, to determine complete response rate after induction ChT as well as&#xD;
      14-16 weeks after the therapy, completion of ChRT to determine disease free survival at 2&#xD;
      years, overall survival at 2 years and late toxicity including thyroid function.&#xD;
&#xD;
      Given the preliminary nature of the study, no stopping rule is prospectively planned outside&#xD;
      of observed toxicity, which will be assessed and graded according to Common Terminology&#xD;
      Criteria for Adverse Events version 3.0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>locoregional control</measure>
    <time_frame>at 2 years post-therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>feasibility (toxicity profile) of the proposed regimen</measure>
    <time_frame>during therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response rate</measure>
    <time_frame>after induction ChT and 14-16 weeks after the therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>at 2 years post-therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>at 2 years post-therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity including thyroid function</measure>
    <time_frame>up to 2 years post-therapy</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, cisplatin, 5-fluorouracil</intervention_name>
    <description>docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab, cisplatin</intervention_name>
    <description>cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20&#xD;
cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)</description>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Squamous cell carcinoma, histologically proven&#xD;
&#xD;
          -  Tumour site: oral cavity, oropharynx, hypopharynx or larynx.&#xD;
&#xD;
          -  Locally and/or regionally inoperable tumors (UICC TNM stages IVa or IVb) - - without&#xD;
             distant metastases (M0-stage)&#xD;
&#xD;
          -  Male or female ≥18 years of age&#xD;
&#xD;
          -  Expected survival &gt;6 months&#xD;
&#xD;
          -  Presence of at least one bidimensionally measurable index lesion&#xD;
&#xD;
          -  Effective contraception for both male and female subjects if risk of conception exists&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Laboratory parameters:&#xD;
&#xD;
        hemoglobin ≥100 g/L leukocyte count &gt; 3.5x109/L, absolute neutrophil count ≥ 1.5x109/L&#xD;
        platelet count &gt; 100x109/L total bilirubin &lt; 1.25x upper normal limit transaminases (ALT,&#xD;
        AST) &lt; 5x upper normal limit creatinine clearance ≥ 55 mls/minute&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Squamous cell carcinoma of the nasopharynx and nasal cavity and paranasal sinuses&#xD;
&#xD;
          -  ChT or XRT ineligibility:&#xD;
&#xD;
        Unstable cardiac disease or any other medical condition likely to compromise the safe&#xD;
        delivery of ChT or XRT; Clinically evident hearing impairment; Pre-existing motor or&#xD;
        sensory neurotoxicity grade ≥ 2 according to the CTCAE v3.0;&#xD;
&#xD;
          -  Any kind of previous therapy for SCCHN (excluding diagnostic biopsy)&#xD;
&#xD;
          -  Previous administration of EGFR pathway-targeting therapy&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy which is&#xD;
             not part of the study protocol&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to study entry&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  History of severe acute pulmonary disease&#xD;
&#xD;
          -  Any investigational agent within past 30 days&#xD;
&#xD;
          -  Other previous malignancy within 5 years, with exception of a history of a previously&#xD;
             adequately treated basal cell carcinoma of the skin or pre- invasive carcinoma of the&#xD;
             cervix&#xD;
&#xD;
          -  Known drug abuse / severe alcohol abuse&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Medical or psychological condition which in the opinion of the investigator would not&#xD;
             permit the subject to complete the study or sign meaningful informed consent&#xD;
&#xD;
          -  Active, uncontrolled infection&#xD;
&#xD;
          -  Other medical condition or other therapy that in the opinion of the investigator&#xD;
             precludes the safe administration of the planned ChT and XRT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Primož Strojan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Radiation Oncology, Institute of Oncology Ljubljana, Slovenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>SI-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>October 23, 2011</last_update_submitted>
  <last_update_submitted_qc>October 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>inoperable</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>concomitant radiochemotherapy</keyword>
  <keyword>biological agent</keyword>
  <keyword>efficacy</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

